Credit: Shutterstock
April 10, 2024 07:00 AM EDT
Financing
Deals
Bioregnum

Big come­back? The Q1 re­port on biotech is in, and there’s been some sput­ter­ing

John Carroll

Editor & Founder

Deal­For­ma’s Chris Doko­ma­ji­lar has been run­ning the num­bers again and backs up some of the things we were al­ready pret­ty sure about — while rais­ing new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times